rs142306293
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 0P and 11B. BP4_ModerateBP6BS1BS2
The NM_021098.3(CACNA1H):c.2264G>A(p.Gly755Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00028 in 1,608,392 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. G755G) has been classified as Likely benign.
Frequency
Consequence
NM_021098.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1H | NM_021098.3 | c.2264G>A | p.Gly755Asp | missense_variant | 10/35 | ENST00000348261.11 | NP_066921.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1H | ENST00000348261.11 | c.2264G>A | p.Gly755Asp | missense_variant | 10/35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
CACNA1H | ENST00000565831.6 | c.2264G>A | p.Gly755Asp | missense_variant | 9/33 | 1 | ENSP00000455840.1 | |||
CACNA1H | ENST00000638323.1 | c.2225G>A | p.Gly742Asp | missense_variant | 10/35 | 5 | ENSP00000492267.1 | |||
CACNA1H | ENST00000639478.1 | n.2264G>A | non_coding_transcript_exon_variant | 10/35 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000640028.1 | n.*177G>A | non_coding_transcript_exon_variant | 10/35 | 5 | ENSP00000491488.1 | ||||
CACNA1H | ENST00000640028.1 | n.*177G>A | 3_prime_UTR_variant | 10/35 | 5 | ENSP00000491488.1 |
Frequencies
GnomAD3 genomes AF: 0.000315 AC: 48AN: 152210Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000252 AC: 59AN: 234368Hom.: 0 AF XY: 0.000256 AC XY: 33AN XY: 128768
GnomAD4 exome AF: 0.000277 AC: 403AN: 1456066Hom.: 0 Cov.: 32 AF XY: 0.000264 AC XY: 191AN XY: 723898
GnomAD4 genome AF: 0.000315 AC: 48AN: 152326Hom.: 0 Cov.: 33 AF XY: 0.000228 AC XY: 17AN XY: 74486
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 10, 2024 | Variant summary: CACNA1H c.2264G>A (p.Gly755Asp) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00025 in 234368 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in CACNA1H causing Idiopathic Generalized Epilepsy, allowing no conclusion about variant significance. c.2264G>A has been reported in the literature in individual(s) affected with Idiopathic Generalized Epilepsy without association with a specific epilepsy phenotype (Heron_2004). These report(s) do not provide unequivocal conclusions about association of the variant with Idiopathic Generalized Epilepsy. At least one publication reports experimental evidence evaluating an impact on protein function (Khosravani_2005). These results showed no damaging effect of this variant. The following publications have been ascertained in the context of this evaluation (PMID: 15048902, 15852375). ClinVar contains an entry for this variant (Variation ID: 529573). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Epilepsy, childhood absence, susceptibility to, 6;C4310756:Hyperaldosteronism, familial, type IV Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 10, 2024 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 31, 2018 | - - |
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 06, 2024 | - - |
Epilepsy, childhood absence, susceptibility to, 6 Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Brain Gene Registry | - | Variant interpreted as Uncertain significance and reported on 2/21/2020 by Lab or GTR ID 500057. Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator John Constantino MD PhD from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at